Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted therapeutics.

Breast cancer Drug resistance Immune subtypes Non-genetic heterogeneity Tumor immune microenvironment

Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
12 Jul 2024
Historique:
received: 08 04 2024
revised: 25 05 2024
accepted: 01 07 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: aheadofprint

Résumé

Breast cancer (BC) is a complex and multifactorial disease, driven by genetic alterations that promote tumor growth and progression. However, recent research has highlighted the importance of non-genetic factors in shaping cancer evolution and influencing therapeutic outcomes. Non-genetic heterogeneity refers to diverse subpopulations of cancer cells within breast tumors, exhibiting distinct phenotypic and functional properties. These subpopulations can arise through various mechanisms, including clonal evolution, genetic changes, epigenetic changes, and reversible phenotypic transitions. Although genetic and epigenetic changes are important points of the pathology of breast cancer yet, the immune system also plays a crucial role in its progression. In clinical management, histologic and molecular classification of BC are used. Immunological subtyping of BC has gained attention in recent years as compared to traditional techniques. Intratumoral heterogeneity revealed by immunological microenvironment (IME) has opened novel opportunities for immunotherapy research. This systematic review is focused on non-genetic variability to identify and interlink immunological subgroups in breast cancer. This review provides a deep understanding of adaptive methods adopted by tumor cells to withstand changes in the tumor microenvironment and selective pressure imposed by medications. These adaptive methods include alterations in drug targets, immune system evasion, activation of survival pathways, and alterations in metabolism. Understanding non-genetic heterogeneity is essential for the development of targeted therapies.

Identifiants

pubmed: 39002207
pii: S1936-5233(24)00182-7
doi: 10.1016/j.tranon.2024.102055
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102055

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mudassir Hassan (M)

Department of Zoology, Government College University Faisalabad, Faisalabad, Punjab 38000, Pakistan.

Lütfi Tutar (L)

Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Kırsehir Ahi Evran University, Kırsehir, Turkey.

Duygu Sari-Ak (D)

Department of Medical Biology, Hamidiye International School of Medicine, University of Health Sciences, Istanbul 34668, Turkey.

Azhar Rasul (A)

Department of Zoology, Government College University Faisalabad, Faisalabad, Punjab 38000, Pakistan.

Ejaz Basheer (E)

Department of Pharmacognosy, Faculty of Pharmaceutical, Sciences Government College University Faisalabad, Pakistan.

Yusuf Tutar (Y)

Faculty of Medicine, Division of Biochemistry, Recep Tayyip Erdogan University, Rize, Turkey. Electronic address: yusuf.tutar@erdogan.edu.tr.

Classifications MeSH